Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker
This prespecified subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to examine the non-inferiority of esaxerenone to trichlormethiazide as a second-line antihypertensive agent according to the basal antihypertensive agent used (angiotensin receptor blocker...
Gespeichert in:
| Veröffentlicht in: | Hypertension research 2024-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Hypertension research |
| container_volume | |
| creator | Kario, Kazuomi Ohbayashi, Hiroyuki Hashimoto, Masami Itabashi, Naoki Kato, Mitsutoshi Uchiyama, Kazuaki Hirano, Kunio Nakamura, Noriko Miyamoto, Takahide Nagashima, Hirotaka Ishida, Hidenori Ebe, Yusuke Hatta, Tsuguru Fukui, Toshiki Shimosawa, Tatsuo Katsuya, Tomohiro Taguchi, Takashi Tanabe, Ayumi Ohishi, Mitsuru |
| description | This prespecified subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to examine the non-inferiority of esaxerenone to trichlormethiazide as a second-line antihypertensive agent according to the basal antihypertensive agent used (angiotensin receptor blocker [ARB] or calcium channel blocker [CCB]). The primary endpoint, change in morning home systolic/diastolic blood pressure (SBP/DBP) from baseline to end of treatment was similar between the two groups (intergroup difference in least squares mean change [95% confidence interval]: -1.3 [-3.8, 1.3]/-0.2 [-1.6, 1.3] mmHg for ARB; -2.7 [-4.2, -1.2]/-0.8 [-1.7, 0.1] mmHg for CCB). The respective incidences of serum potassium levels |
| doi_str_mv | 10.1038/s41440-024-01887-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3115771482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3115771482</sourcerecordid><originalsourceid>FETCH-LOGICAL-c228t-aae7f0c36f4f9544c349983f7e127e2fa23cb26d4770061b463e6af8c6a68b883</originalsourceid><addsrcrecordid>eNpNkU9v1DAQxS0EokvhC3BAPnJx8b91HG5otbCVKnFZJG6R44wbg2MHOylsPzjnZrtbxGlGmjfvzeiH0FtGrxgV-kORTEpKKJeEMq0rwp6hFRNSE8mZfI5WtGaK1EqoC_SqlB-Ucr2u2Ut0IWpRyzXjK_R3lwbAbUipw2OGUuYMJKTfkH28xeAc2Aknh6GYP5Ahpgj4DnKZC56yt31IeYCp9-bed4BdyniONsUppxCgw_1hhDxBLD7Fj9gcIzpwPi6jMrcmmnAovhwDph7w9vvmer8luz3OJnZp8PeL7j-3JdEE3B5wa8rSWBOsnwdsexMjhOMX9ifkp_tMvPXpMTviDBbGabnurHmNXjgTCrw510v07fN2v9mRm69frjefbojlXE_EGKgctUI56eq1lFbIutbCVcB4BdwZLmzLVSerilLFWqkEKOO0VUbpVmtxid6ffMecfs1QpmbwxUIIJkKaSyMYW1cVk5ovUn6S2pxKyeCaMfvB5EPDaHPk3Zx4Nwvv5pF3w5ald2f_uR2g-7fyBFg8AD4Drno</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3115771482</pqid></control><display><type>article</type><title>Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker</title><source>Alma/SFX Local Collection</source><creator>Kario, Kazuomi ; Ohbayashi, Hiroyuki ; Hashimoto, Masami ; Itabashi, Naoki ; Kato, Mitsutoshi ; Uchiyama, Kazuaki ; Hirano, Kunio ; Nakamura, Noriko ; Miyamoto, Takahide ; Nagashima, Hirotaka ; Ishida, Hidenori ; Ebe, Yusuke ; Hatta, Tsuguru ; Fukui, Toshiki ; Shimosawa, Tatsuo ; Katsuya, Tomohiro ; Taguchi, Takashi ; Tanabe, Ayumi ; Ohishi, Mitsuru</creator><creatorcontrib>Kario, Kazuomi ; Ohbayashi, Hiroyuki ; Hashimoto, Masami ; Itabashi, Naoki ; Kato, Mitsutoshi ; Uchiyama, Kazuaki ; Hirano, Kunio ; Nakamura, Noriko ; Miyamoto, Takahide ; Nagashima, Hirotaka ; Ishida, Hidenori ; Ebe, Yusuke ; Hatta, Tsuguru ; Fukui, Toshiki ; Shimosawa, Tatsuo ; Katsuya, Tomohiro ; Taguchi, Takashi ; Tanabe, Ayumi ; Ohishi, Mitsuru ; EXCITE-HT investigators ; on behalf of the EXCITE-HT investigators</creatorcontrib><description>This prespecified subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to examine the non-inferiority of esaxerenone to trichlormethiazide as a second-line antihypertensive agent according to the basal antihypertensive agent used (angiotensin receptor blocker [ARB] or calcium channel blocker [CCB]). The primary endpoint, change in morning home systolic/diastolic blood pressure (SBP/DBP) from baseline to end of treatment was similar between the two groups (intergroup difference in least squares mean change [95% confidence interval]: -1.3 [-3.8, 1.3]/-0.2 [-1.6, 1.3] mmHg for ARB; -2.7 [-4.2, -1.2]/-0.8 [-1.7, 0.1] mmHg for CCB). The respective incidences of serum potassium levels <3.5 mEq/L and ≥5.5 mEq/L in the ARB subgroup were 3.4% and 4.2% for esaxerenone and 7.9% and 0% for trichlormethiazide; in the CCB subgroup, they were 2.8% and 0.6% for esaxerenone and 13.9% and 1.2% for trichlormethiazide, respectively. The incidence of uric acid level ≥7.0 mg/dL was numerically higher in the trichlormethiazide group than the esaxerenone group in both the ARB and CCB subgroups. The non-inferiority of esaxerenone to trichlormethiazide in lowering morning home BP was demonstrated regardless of whether the basal antihypertensive agent was an ARB or CCB. Esaxerenone with a CCB showed superiority to trichlormethiazide in lowering SBP, without any new safety concerns. Serum potassium levels tended to be higher when esaxerenone was combined with an ARB than with a CCB, but this can be mitigated if administered according to the package insert. A subgroup analysis of the EXCITE-HT study according to basal antihypertensive agent demonstrated the non-inferiority of esaxerenone to trichlormethiazide in lowering morning home BP regardless irrespective of the basal antihypertensive agent. Esaxerenone with a CCB showed superiority to trichlormethiazide in lowering SBP, without any new safety concerns.</description><identifier>ISSN: 0916-9636</identifier><identifier>ISSN: 1348-4214</identifier><identifier>EISSN: 1348-4214</identifier><identifier>DOI: 10.1038/s41440-024-01887-1</identifier><identifier>PMID: 39394512</identifier><language>eng</language><publisher>England</publisher><ispartof>Hypertension research, 2024-10</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c228t-aae7f0c36f4f9544c349983f7e127e2fa23cb26d4770061b463e6af8c6a68b883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39394512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Ohbayashi, Hiroyuki</creatorcontrib><creatorcontrib>Hashimoto, Masami</creatorcontrib><creatorcontrib>Itabashi, Naoki</creatorcontrib><creatorcontrib>Kato, Mitsutoshi</creatorcontrib><creatorcontrib>Uchiyama, Kazuaki</creatorcontrib><creatorcontrib>Hirano, Kunio</creatorcontrib><creatorcontrib>Nakamura, Noriko</creatorcontrib><creatorcontrib>Miyamoto, Takahide</creatorcontrib><creatorcontrib>Nagashima, Hirotaka</creatorcontrib><creatorcontrib>Ishida, Hidenori</creatorcontrib><creatorcontrib>Ebe, Yusuke</creatorcontrib><creatorcontrib>Hatta, Tsuguru</creatorcontrib><creatorcontrib>Fukui, Toshiki</creatorcontrib><creatorcontrib>Shimosawa, Tatsuo</creatorcontrib><creatorcontrib>Katsuya, Tomohiro</creatorcontrib><creatorcontrib>Taguchi, Takashi</creatorcontrib><creatorcontrib>Tanabe, Ayumi</creatorcontrib><creatorcontrib>Ohishi, Mitsuru</creatorcontrib><creatorcontrib>EXCITE-HT investigators</creatorcontrib><creatorcontrib>on behalf of the EXCITE-HT investigators</creatorcontrib><title>Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker</title><title>Hypertension research</title><addtitle>Hypertens Res</addtitle><description>This prespecified subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to examine the non-inferiority of esaxerenone to trichlormethiazide as a second-line antihypertensive agent according to the basal antihypertensive agent used (angiotensin receptor blocker [ARB] or calcium channel blocker [CCB]). The primary endpoint, change in morning home systolic/diastolic blood pressure (SBP/DBP) from baseline to end of treatment was similar between the two groups (intergroup difference in least squares mean change [95% confidence interval]: -1.3 [-3.8, 1.3]/-0.2 [-1.6, 1.3] mmHg for ARB; -2.7 [-4.2, -1.2]/-0.8 [-1.7, 0.1] mmHg for CCB). The respective incidences of serum potassium levels <3.5 mEq/L and ≥5.5 mEq/L in the ARB subgroup were 3.4% and 4.2% for esaxerenone and 7.9% and 0% for trichlormethiazide; in the CCB subgroup, they were 2.8% and 0.6% for esaxerenone and 13.9% and 1.2% for trichlormethiazide, respectively. The incidence of uric acid level ≥7.0 mg/dL was numerically higher in the trichlormethiazide group than the esaxerenone group in both the ARB and CCB subgroups. The non-inferiority of esaxerenone to trichlormethiazide in lowering morning home BP was demonstrated regardless of whether the basal antihypertensive agent was an ARB or CCB. Esaxerenone with a CCB showed superiority to trichlormethiazide in lowering SBP, without any new safety concerns. Serum potassium levels tended to be higher when esaxerenone was combined with an ARB than with a CCB, but this can be mitigated if administered according to the package insert. A subgroup analysis of the EXCITE-HT study according to basal antihypertensive agent demonstrated the non-inferiority of esaxerenone to trichlormethiazide in lowering morning home BP regardless irrespective of the basal antihypertensive agent. Esaxerenone with a CCB showed superiority to trichlormethiazide in lowering SBP, without any new safety concerns.</description><issn>0916-9636</issn><issn>1348-4214</issn><issn>1348-4214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkU9v1DAQxS0EokvhC3BAPnJx8b91HG5otbCVKnFZJG6R44wbg2MHOylsPzjnZrtbxGlGmjfvzeiH0FtGrxgV-kORTEpKKJeEMq0rwp6hFRNSE8mZfI5WtGaK1EqoC_SqlB-Ucr2u2Ut0IWpRyzXjK_R3lwbAbUipw2OGUuYMJKTfkH28xeAc2Aknh6GYP5Ahpgj4DnKZC56yt31IeYCp9-bed4BdyniONsUppxCgw_1hhDxBLD7Fj9gcIzpwPi6jMrcmmnAovhwDph7w9vvmer8luz3OJnZp8PeL7j-3JdEE3B5wa8rSWBOsnwdsexMjhOMX9ifkp_tMvPXpMTviDBbGabnurHmNXjgTCrw510v07fN2v9mRm69frjefbojlXE_EGKgctUI56eq1lFbIutbCVcB4BdwZLmzLVSerilLFWqkEKOO0VUbpVmtxid6ffMecfs1QpmbwxUIIJkKaSyMYW1cVk5ovUn6S2pxKyeCaMfvB5EPDaHPk3Zx4Nwvv5pF3w5ald2f_uR2g-7fyBFg8AD4Drno</recordid><startdate>20241012</startdate><enddate>20241012</enddate><creator>Kario, Kazuomi</creator><creator>Ohbayashi, Hiroyuki</creator><creator>Hashimoto, Masami</creator><creator>Itabashi, Naoki</creator><creator>Kato, Mitsutoshi</creator><creator>Uchiyama, Kazuaki</creator><creator>Hirano, Kunio</creator><creator>Nakamura, Noriko</creator><creator>Miyamoto, Takahide</creator><creator>Nagashima, Hirotaka</creator><creator>Ishida, Hidenori</creator><creator>Ebe, Yusuke</creator><creator>Hatta, Tsuguru</creator><creator>Fukui, Toshiki</creator><creator>Shimosawa, Tatsuo</creator><creator>Katsuya, Tomohiro</creator><creator>Taguchi, Takashi</creator><creator>Tanabe, Ayumi</creator><creator>Ohishi, Mitsuru</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241012</creationdate><title>Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker</title><author>Kario, Kazuomi ; Ohbayashi, Hiroyuki ; Hashimoto, Masami ; Itabashi, Naoki ; Kato, Mitsutoshi ; Uchiyama, Kazuaki ; Hirano, Kunio ; Nakamura, Noriko ; Miyamoto, Takahide ; Nagashima, Hirotaka ; Ishida, Hidenori ; Ebe, Yusuke ; Hatta, Tsuguru ; Fukui, Toshiki ; Shimosawa, Tatsuo ; Katsuya, Tomohiro ; Taguchi, Takashi ; Tanabe, Ayumi ; Ohishi, Mitsuru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c228t-aae7f0c36f4f9544c349983f7e127e2fa23cb26d4770061b463e6af8c6a68b883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Ohbayashi, Hiroyuki</creatorcontrib><creatorcontrib>Hashimoto, Masami</creatorcontrib><creatorcontrib>Itabashi, Naoki</creatorcontrib><creatorcontrib>Kato, Mitsutoshi</creatorcontrib><creatorcontrib>Uchiyama, Kazuaki</creatorcontrib><creatorcontrib>Hirano, Kunio</creatorcontrib><creatorcontrib>Nakamura, Noriko</creatorcontrib><creatorcontrib>Miyamoto, Takahide</creatorcontrib><creatorcontrib>Nagashima, Hirotaka</creatorcontrib><creatorcontrib>Ishida, Hidenori</creatorcontrib><creatorcontrib>Ebe, Yusuke</creatorcontrib><creatorcontrib>Hatta, Tsuguru</creatorcontrib><creatorcontrib>Fukui, Toshiki</creatorcontrib><creatorcontrib>Shimosawa, Tatsuo</creatorcontrib><creatorcontrib>Katsuya, Tomohiro</creatorcontrib><creatorcontrib>Taguchi, Takashi</creatorcontrib><creatorcontrib>Tanabe, Ayumi</creatorcontrib><creatorcontrib>Ohishi, Mitsuru</creatorcontrib><creatorcontrib>EXCITE-HT investigators</creatorcontrib><creatorcontrib>on behalf of the EXCITE-HT investigators</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kario, Kazuomi</au><au>Ohbayashi, Hiroyuki</au><au>Hashimoto, Masami</au><au>Itabashi, Naoki</au><au>Kato, Mitsutoshi</au><au>Uchiyama, Kazuaki</au><au>Hirano, Kunio</au><au>Nakamura, Noriko</au><au>Miyamoto, Takahide</au><au>Nagashima, Hirotaka</au><au>Ishida, Hidenori</au><au>Ebe, Yusuke</au><au>Hatta, Tsuguru</au><au>Fukui, Toshiki</au><au>Shimosawa, Tatsuo</au><au>Katsuya, Tomohiro</au><au>Taguchi, Takashi</au><au>Tanabe, Ayumi</au><au>Ohishi, Mitsuru</au><aucorp>EXCITE-HT investigators</aucorp><aucorp>on behalf of the EXCITE-HT investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker</atitle><jtitle>Hypertension research</jtitle><addtitle>Hypertens Res</addtitle><date>2024-10-12</date><risdate>2024</risdate><issn>0916-9636</issn><issn>1348-4214</issn><eissn>1348-4214</eissn><abstract>This prespecified subanalysis of the multicenter, randomized, open-label, parallel-group EXCITE-HT study aimed to examine the non-inferiority of esaxerenone to trichlormethiazide as a second-line antihypertensive agent according to the basal antihypertensive agent used (angiotensin receptor blocker [ARB] or calcium channel blocker [CCB]). The primary endpoint, change in morning home systolic/diastolic blood pressure (SBP/DBP) from baseline to end of treatment was similar between the two groups (intergroup difference in least squares mean change [95% confidence interval]: -1.3 [-3.8, 1.3]/-0.2 [-1.6, 1.3] mmHg for ARB; -2.7 [-4.2, -1.2]/-0.8 [-1.7, 0.1] mmHg for CCB). The respective incidences of serum potassium levels <3.5 mEq/L and ≥5.5 mEq/L in the ARB subgroup were 3.4% and 4.2% for esaxerenone and 7.9% and 0% for trichlormethiazide; in the CCB subgroup, they were 2.8% and 0.6% for esaxerenone and 13.9% and 1.2% for trichlormethiazide, respectively. The incidence of uric acid level ≥7.0 mg/dL was numerically higher in the trichlormethiazide group than the esaxerenone group in both the ARB and CCB subgroups. The non-inferiority of esaxerenone to trichlormethiazide in lowering morning home BP was demonstrated regardless of whether the basal antihypertensive agent was an ARB or CCB. Esaxerenone with a CCB showed superiority to trichlormethiazide in lowering SBP, without any new safety concerns. Serum potassium levels tended to be higher when esaxerenone was combined with an ARB than with a CCB, but this can be mitigated if administered according to the package insert. A subgroup analysis of the EXCITE-HT study according to basal antihypertensive agent demonstrated the non-inferiority of esaxerenone to trichlormethiazide in lowering morning home BP regardless irrespective of the basal antihypertensive agent. Esaxerenone with a CCB showed superiority to trichlormethiazide in lowering SBP, without any new safety concerns.</abstract><cop>England</cop><pmid>39394512</pmid><doi>10.1038/s41440-024-01887-1</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0916-9636 |
| ispartof | Hypertension research, 2024-10 |
| issn | 0916-9636 1348-4214 1348-4214 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3115771482 |
| source | Alma/SFX Local Collection |
| title | Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T08%3A58%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Home%20blood%20pressure-lowering%20effect%20of%20esaxerenone%20versus%20trichlormethiazide%20for%20uncontrolled%20hypertension:%20a%20predefined%20subanalysis%20of%20the%20EXCITE-HT%20randomized%20controlled%20trial%20by%20basal%20calcium%20channel%20blocker%20versus%20angiotensin%20receptor%20blocker&rft.jtitle=Hypertension%20research&rft.au=Kario,%20Kazuomi&rft.aucorp=EXCITE-HT%20investigators&rft.date=2024-10-12&rft.issn=0916-9636&rft.eissn=1348-4214&rft_id=info:doi/10.1038/s41440-024-01887-1&rft_dat=%3Cproquest_cross%3E3115771482%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3115771482&rft_id=info:pmid/39394512&rfr_iscdi=true |